ArticleCureus2025
Cutting Through the Debate: Surgical Resection Versus Surveillance-Based Approach for Kikuchi SM2/3 Colorectal Polyps.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Malignant colorectal polyps are cancer lesions that invade the submucosa but do not extend into the muscularis propria. The Kikuchi system of malignant polyp classification is used for sessile polyps and describes the depth of cancer invasion into the submucosa (SM1-3). With deeper submucosal invasions (SM2 and SM3), the risk of lymph node involvement is higher. Therefore, these patients should be considered for prophylactic surgical resection. Despite this, we have noted a greater inclination toward a surveillance-based approach for Kikuchi SM2/3 malignant colorectal polyps due to the absence of clear guidelines regarding the management of sessile polyps. This study aimed to compare the prognostic benefits of a surveillance-based and surgical approach in patients with Kikuchi SM2/3 polyps by evaluating the rate of recurrence and case fatality. Methodology This retrospective cohort study evaluated the oncological outcomes of a surveillance-based approach versus prophylactic colectomy in Kikuchi SM2 and SM3 polyps identified in individuals participating in the UK's National Bowel Cancer Screening Programme. The study was conducted at New Cross Hospital in Wolverhampton, United Kingdom, over a 14-year period, from February 2009 to February 2023. Patients with pedunculated polyps, lower Kikuchi classification, and histologically unassessable polyp classification were excluded. Data analysis was performed using SPSS Statistics for Windows, Version 24.0 (IBM Corp., Armonk, NY, USA). Results This study included 70 sessile polyps with a Kikuchi classification of SM2. Of the 70 cases studied, 23 opted for surgical resection, while 47 chose surveillance-based management. No significant differences in baseline demographics (age and gender) were observed between the groups. Oncological outcomes revealed that the degree of endoscopic and biochemical recurrence was significantly higher in the surveillance group versus the surgical group. Cancer-related mortality was statistically significantly lower in the surgical group. Radiological recurrence was lower in the surgical group but not statistically significant. Metastatic lymph node involvement in the surgical group was significant. Conclusions This study suggests that the surgical management of Kikuchi SM2 malignant colorectal polyps offers better prognostic outcomes, with lower rates of cancer-related mortality and fewer patients developing clinical recurrence. Surgeons may consider these practices based on the study findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.